Incidence of Lower Limb Amputation in Diabetic Patients in Osijek-Baranja County by Silvija Canecki-Varžić et al.
147
Received for publication August 15, 2020
Introduction
Diabetes mellitus (DM) is a major risk factor for all 
forms of cardiovascular disease, which is the most com-
mon cause of death for patients with diabetes¹. DM is also 
a strong risk factor for peripheral artery disease (PAD), 
defined as atherosclerosis in lower extremity arteries or 
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A B S T R A C T
Amputation of the lower limb (LLA) is one of the most feared adverse outcomes among diabetic patients. Our aim was 
to determine the incidence of amputation in diabetic patients in Osijek-Baranja County and to examine the possible cor-
relation between clinical characteristics of the patients and the time elapsed before the first amputation. This was a 
tertiary-care-based retrospective study and included 925 diabetic patients who underwent non-traumatic lower limb 
amputation in the University Hospital Osijek from January 1st 2008 to December 31st 2018. Data on associated cardio-
vascular risk factors and clinical characteristics of the patients were collected from diabetic registry of the Department 
of diabetes and endocrinology. A total of 278 patients had all data for further analysis. There were 1551 LLAs over a ten 
year period. The incidence was 6.14 per 1,000 adults with diabetes. LLA rates per 1,000 adults with diabetes decreased 
by 29% between 2010 and 2013 and then increased by 76% between 2014 and 2018. In ten year period incidence of am-
putation in diabetic patients varied from 4 to 7.8 per 1000 persons-year. We observed the same pattern in both minor and 
major LLA but rates of amputation above knee steadily increased 2.7 times between 2010 and 2018 (from 0.69 to 1.83 per 
1000 patients-year). The mean age of patients with LLA was 67.2 years, 66% were male, mean BMI was 29.6±4.8 kg/m2 
and the mean duration of diabetes was 14.7±8.2 years. There was no association between smoking, arterial hypertension 
and hyperlipemia, ACE inhibitor use, statin use, antiplatelet use, CVD, neuropathy and duration of diabetes before 
first amputation. Only sulphonylurea and insulin therapy significantly prolonged the time before the first amputation 
(p = 0.00001, for each).  In conclusion, our study confirmed high rate of lower limb amputation in diabetic patients in 
Osijek-Baranja County. Incidence rates of LLA in our population are important for further improvements in diabetes care 
and decisions in health care policy.
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LEAD². PAD is an important predictor of ulceration of the 
foot and limb loss in diabetic patients². It is present in 50% 
of patients with diabetic foot ulceration a proportion which 
may be increasing2,3. Patients with diabetes and PAD have 
an increased risk of adverse cardiac and limb events3,4. 
Lower extremity amputation (LEA) is one of the most dev-
astating consequences of PAD and diabetic foot ulceration. 
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LEAs reduce the quality of life5 and increase mortality6 
as well as medical costs7.
USA National surveillance data showed that rates of 
non-traumatic LEA declined by about half between 1990 
and 2010 mainly by improving diabetes control, screening 
and detection of vascular disease and revascularization 
techniques thus minimizing the onset of complications 
such as PAD and neuropathy8,9. However, the most recent 
trends in USA showed the increase in rates of total, major, 
and minor amputations which were most pronounced in 
young and middle-aged adults and may indicate a reversal 
in the progress of diabetes care10.
There are significant geographic variations in the 
rates of LLA between different countries11 and across the 
USA and UK12. To our knowledge there is no data about 
LLA incidence in Croatia either in diabetics or in non-
diabetics. Our aim was to determine the incidence of am-
putation in patients with diabetes mellitus in Osijek-Ba-
ranja County and to examine the possible correlation 
between cardiovascular risk factors and other specific 
clinical and general characteristics of the patients and the 
time elapsed before the first amputation.
Methods 
This was a tertiary-care-based retrospective study in-
volving adult patients in whom amputation were per-
formed for reasons relating to complication of PAD and/or 
diabetes in the Department of vascular surgery, Univer-
sity Hospital Centre Osijek from 1st January 2008 to 31st 
December 2018. This study complied with the Declaration 
of Helsinki and was approved by ethics committee of Uni-
versity Hospital Osijek. Informed and written consent was 
not required by the ethics committee, this waiver was due 
to the retrospective nature of our study. No personal data 
that could be linked to a patient were used. Patient with 
diabetes were defined as those with discharged diagnosis 
diabetes mellitus or code E10-13. LLAs were categorized 
by level of amputation as follows: minor amputation (toe 
and foot) and major amputation (above foot and below 
knee, and above knee). If there was more than one opera-
tion during a single admission, only one (the highest) was 
counted, but when amputations occurred during separate 
admissions they were counted as separate episodes. We 
calculated LLA rates using estimates of the population 
with diabetes derived from CroDiab registry and Croatian 
Institute for Public Health for our county. Data on associ-
ated cardiovascular risk factors (arterial hypertension, 
hyperlipidemia, smoking) and other clinical characteris-
tics (age, gender, type of diabetes, duration of diabetes, 
diabetic therapy, complications of diabetes) of the patients 
were collected from diabetic registry of the Department of 
diabetes and endocrinology. A total of 278 patients had all 
data for further analysis.
Statistical analysis 
We described data using means and medians and com-
pared them using either the Student t-test or Mann Whit-
ney U-test for paired comparisons depending on whether 
the variables were parametric or non-parametric. We 
tested differences in frequencies for significance using the 
Chi-square test or Fishers Exact tests. Association be-
tween the time elapsed before the first amputation and 
smoking, diabetic therapy and other clinical characteris-
tics were analyzed using Spearman’s rank correlation 
coefficient. We created Cox proportional hazard regression 
analysis models to determine factors that predicted the 
time elapsed before the first amputation.
Results
There were 1551 LLAs in ten year period. Smaller pro-
portion of amputations were major amputations i.e. above 
foot (49.3% vs. 59.3%). The incidence was 6.14 for 1,000 
adults with diabetes. LLA rates per 1,000 adults with dia-
betes per year decreased by 29% between 2010 and 2013 
and then increased by 76% between 2014 and 2018 (Figure 
1). In ten year period incidence of amputation in diabetic 
patients varied from 4 to 7.8 per 1000 patients-year with 
increasing trend from 2014 to 2018. We observed the same 
pattern in both minor and major LLA but rates of amputa-
tion above knee steadily increased 2.65 times between 
2010 and 2018 (from 0.69 to 1.83 per 1000 patients-year).
Among 925 diabetic patients with LLA we identified a 
group of 278 patients with complete clinical data for fur-
ther analysis. Their characteristics are shown in Table 1. 
The mean age of patients with LLA was 67.2 years, 66% 
were male, almost all diabetes-related LLA occurred in 
Fig. 1. Total, minor and major lower limb amputation incidence per 1,000 diabetic patient per year
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At the time of amputation 46% of diabetic patients were 
taking oral diabetic drugs (Table 2), mostly sulfonylureas 
(80%), only 33% were taking metformin. At the time of 
amputation 51% of patients were on insulin therapy. ACE 
type 2 diabetes patients (94%) and the mean duration of 
diabetes was 14.7±8.2 years. Metabolic control was poor 
(HbA1c 9.1±1.9%), and they were overweight and/or obese 
(BMI 29.6±4.8 kg/m2).
TABLE 1




Percentage (%) Mean SD Median IQR
Gender 
Females   94 34 
Males 184 66
Age (years) 67.24 10.39 68.00 60.00–75.00
Type of diabetes 
1   13   5
2 262 94 
NK     3   1
Duration of 
diabetes (years) 14.73   8.19 15.00 9.00–20.00
HbA1c   9.12   1.86   9.30 7.70–10.40
BMI (kg/m2) 29.63   4.76 29.10 26.40–32.10
HbA1c – glycated hemoglobin, BMI – body mass index, SD – standard deviation, 






Percentage(%) Mean SD Median IQR
Oral antidiabetics 

































NK – not known 
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inhibitors had 40%, statin had 53% and antiplatelet ther-
apy 27% of patients. 
Tables 3 and 4 show CVD, CVD risk factors and dia-
betic complications at time of amputation. There was no 
association between smoking, arterial hypertension and 
hyperlipidemia and duration of diabetes before the first 
amputation (Table 4). Also, there was no association be-
tween ACE inhibitor use, statin use, antiplatelet use and 
diabetes duration before first amputation (Table 5). CVD 
and neuropathy had no impact on the time elapsed before 
the first amputation. 
When we look at the association between oral diabetic 
drug and the time elapsed before the first amputation 
(Table 6), only sulfonylurea and insulin therapy signifi-
cantly prolonged the time before the first amputation 
(p=0.00001, for each). For DPP4 inhibitors there was non-
significant association (p=0.06) probably due to a small 
number of patients (only 19 or 7% of patients). 
Discussion
Our study confirmed high rate of lower limb amputa-
tion in diabetic patients in Osijek-Baranja County. In ten 
year period there were 1551 lower limb amputations in 
925 patients. The incidence was 6.14 for 1,000 adults with 
diabetes. After a decreasing trend in overall LLA inci-
dence, from 2014 to 2018 amputations increased again, 
TABLE 3 









Yes 35 13 
No 218 78 
NK 25 9 
Hystory of 
 ishemic stroke 
Yes 41 15 
No 212 76 
NK 25 9 
Diabetic 
polyneuropathy 
Yes 87 59 
No 165 32 
NK 26 9 
TABLE 4 
ASSOCIATION BETWEEN RISK FACTORS AND DURATION OF DIABETES AT THE TIME OF FIRST AMPUTATION





(%) Mean SD Median IQR p
Arterial 
hypertension 
Yes 219 14.82 8.54 15.00 8.00–20.00 8.00–20.00
0.74
No 59 14.42 7.22 14.00 9.00–19.00 9.00–19.00
Hyperlipidemia 
Yes 158 13.88 7.05 15.00 8.00–19.00 8.00–19.00
0.06
No 118 15.70 9.38 14.50 9.00–21.00 9.00–21.00
Smoking Yes 45 13.80 8.07 16.00 10.00–17.00 10.00–17.00 0.16
SD – standard deviation, IQR – interquartile range, NK – not known 
TABLE 5 
ASSOCIATION BETWEEN CONCOMITANT THERAPY AND DIABETES DURATION AT THE TIME OF FIRST 
AMPUTATION




participants Medijan IQR p
Statins
Yes 148 14.59 7.99 15.00 8.00–19.50
0.72
No 98 14.22 8.23 14.00 9.00–20.00
ACE-inhibitors
Yes 112 14.67 9.03 14.00 8.50–20.00
0.67
No 132 14.23 7.15 14.00 8.50–19.00
Anti platelet 
therapy Yes 75 14.12 6.80 14.00 10.00–19.00 0.66
SD – standard deviation, IQR – interquartile range, NK – not known
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with LLA rates from 4 to 7.8 per 1000 persons-year. The 
same pattern was observed for both minor and major am-
putations. However, the rates of amputations above knee 
steadily increased from 0.69 to 1.83 per 1000 persons-
year, 2.7 times in ten years period. The rate of LLA has 
been considered as an indicator of the quality of diabetic 
foot care reflecting delayed management of diabetic foot 
and diabetic foot complication as well as difficulties in 
diagnosis and treatment of PAD2. In our study there were 
more minor than major amputations. The increase in mi-
nor amputations may reflect a more aggressive clinical 
approach, since earlier toe amputations may prevent more 
serious amputations. Therefore, in our study there was 
considerable increase in minor amputations from 2013 to 
2018. 
In a large international survey of 12 European coun-
tries and New Zealand on amputation rates for PAD from 
2010 to 2014, significant differences were identified be-
tween countries, with the mean incidence of major ampu-
tation being highest in Hungary (41.4/100,000) and lowest 
in New Zealand (7.2/100,000) with an overall declining 
trend for major amputations, except for Slovakia11. In a 
recent meta-analysis of population-based studies on inci-
dence, relative risks and changes of amputation rates over 
time in diabetic and non-diabetic population considerable 
differences between studies were recorded13. The incidence 
of LLA in the diabetic population ranged from 78 to 704 
per 100,000 person-years and the relative risks between 
diabetic and non-diabetic patients varied between 7.4 and 
41.313. In England the incidence of LLA was 2.51 per 1,000 
person-years in people with diabetes12. Moreover, there 
was considerable regional variation within country, and 
the incidence varied tenfold–both for major (range 0.22–
2.20 per 1,000 person-years) and minor ones (range 0.30–
3.25 per 1,000 person-years)12. USA National surveillance 
data showed that rates of  LLAs declined by about half 
between 1990 and 2010 mainly by improving access to 
effective primary care, with improved control of blood 
sugar and interventions to minimize the onset of complica-
tions such as peripheral arterial disease and neuropa-
thy13,14. However, the most recent trends in USA for 2000-
2015 showed that LLA incidence decreased 45% from 
2000-2009, but then rebounded by 50% between 2009 and 
201510. The reversal in amputation rates was driven pri-
marily by increases in younger and middle-aged adults 
and men and may indicate a reversal in the progress of 
diabetes care10. In our study, increase in LLA incidence 
from 2014-2018 may indicate that after improvement in 
previous years (2008-2013) amputation rates in diabetic 
patients again began to increase. Reasons for that reversal 
trend are unclear. It can be due to failures in the preven-
tion of major lower-extremity disease, delayed diagnosis 
and treatment of PAD, poor management of CVD risk fac-
tors and poor glycemic control. It is also possible that 
changes in health policy and organization of diabetes care 
in 2013 and changes in access to effective diabetic care in 
Croatia together with socio-economic factors could have 
affected trends of LLA. 
There are a number of studies in different countries 
that have shown that it is possible to reduce the incidence 
of amputation in diabetes by implementing changes to the 
structure of diabetes foot ulcer care and after introduction 
TABLE 6 
ASSOCIATION BETWEEN ANTIDIABETIC THERAPY AND DIABETES DURATION AT THE TIME OF FIRST 
AMPUTATION
Duration of diabetes (years)
Antidiabetic therapy Number of participants (N) Mean SD Median IQR p
Oral antidiabetics at 
the time of amputation
Yes 127 12.04 6.98 11.00 6.00–17.00
0.000009
No 100 16.94 8.79 16.50 11.50–21.00
Sulfonylurea
Yes 223 15.06 7.69 15.00 10.00–20.00
0.00001
No 20 8.25 6.54 7.00 3.00–12.00
Metformin
Yes 91 14.34 7.04 14.00 10.00–19.00
0.81
No 152 14.59 8.26 15.00 8.00–20.00
Meglitinides
Yes 42 15.33 7.29 15.00 9.00–22.00
0.45
No 200 14.34 7.85 14.50 8.50–19.50
Alfa
Glukozidase inhibitors
Yes 27 16.88 6.50 17.00 13.00–20.00
0.08
No 216 14.20 7.93 14.00 8.00–20.00
DPP – 4 inhibitori
Yes 19 11.36 7.08 11.00 5.00–16.00
0.06
No 218 14.72 7.88 15.00 9.00–20 00
Insulin at the time  
of  amputation
Yes 142 16.30 8.07 16.00 11.00–21.00
0.00001
No 99 11.66 7.65 10.00 5.00–17.00
SD – standard deviation, IQR – interquartile range
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of multidisciplinary team for diabetic foot15,16. However, 
despite the implementation of a care plan for patients with 
diabetes, the incidence of LLA has not fallen in Andalusia 
in recent years17. 
In our study we have analyzed characteristics of pa-
tients which could influence greater amputation risk. The 
mean age of our diabetic patients was over 65 years and 
66% were male. Despite a high prevalence of uncontrolled 
vascular risk factors such as hypertension, hyperlipid-
emia and diabetes, only 54%, 40% and 27% of those with 
LLA were on lipid-lowering, ACE inhibitor and antiplate-
let therapy. Male gender was previously identified as a 
risk factor for PAD and some studies found higher inci-
dence of LLA among men than women in both the dia-
betic and the non-diabetic population13. Moreover, men 
were younger at the time of LLA then women17. The in-
creased amputation rates among men may be explained 
by environmental factors such as smoking as well as by 
a higher prevalence of peripheral vascular disease, pe-
ripheral neuropathy and diabetic foot ulceration. Our 
diabetic patients had poor metabolic control with high 
HbA1c which could reflect serious condition before ampu-
tation, with inflammation and/or sepsis. Good metabolic 
control and diabetes management is very important in 
delaying amputation. In our study only sulfonylurea and 
insulin treatment significantly prolonged time to first 
amputation. Therefore, improvement in diabetes manage-
ment and care, management of CVD risk factors, good 
foot care and early detection of PAD are warranted to 
reduce diabetic complications and prevent amputations in 
diabetic patients.
In conclusion, our study confirmed a high rate of lower 
limb amputation in diabetic patients in Osijek-Baranja 
County which is representative for east Croatia region. 
Regular evaluation of incidence rates of lower limb ampu-
tation in our population are of crucial importance  for 
health policy decision makers and for further improve-
ments in diabetes care. 
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INCIDENCIJA AMPUTACIJA DONJIH EKSTREMITETA U DIJABETIČKIH BOLESNIKA OD 2010. DO 
2018. GODINE U OSJEČKO-BARANJSKOJ ŽUPANIJI
S A Ž E T A K
Amputacija donjih ekstremiteta za dijabetičke bolesnike predstavlja neželjeni ishod kojeg se najviše boje.Cilj našeg 
ispitivanja bio je odrediti kretanje godišnje stope amputacija donjih ekstremiteta u dijabetičkih bolesnika te ispitati 
povezanost između kliničkih značajki bolesnika i trajanja dijabetesa do prve amputacije. Ovo je presiječno retrospe-
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ktivno ispitivanje u tercijarnom centru obuhvatilo 925 dijabetičkih bolesnika kojima je učinjena netraumatska am-
putacija donjih ekstremiteta u razdoblju od 2008. do 2018.g u KBC Osijek. Prikupljeni su podaci iz registra Zavoda za 
endokrinologiju o kardiovaskularnim rizičnim čimbenicima i drugim kliničkim značajkama bolesnika. Za dodatne 
analize izdvojena je skupina od 278 pacijenata koji su imali podatke za daljnju analizu. U desetogodišnjem razdoblju bilo 
je 1551 amputacija donjih ekstremiteta. Incidencija stope amputacija iznosila je 6,14 na 1000 pacijent-godina. Stopa 
amputacija na 1000 pacijent-godina smanjila se za 29% između 2010.i 2013. godine te ponovo porasla na 76% od 2014.–
2018. Godišnja stopa varirala je od 4,0–7,8 amputacija na 1000 pacijent-godina. Isti obrazac registrirali smo za manje 
i veće amputacije, ali stopa amputacija iznad nivoa koljena postojano je rasla i od 2010. do 2018. g. povećala se 2,7 puta 
(od 0,69 na 1,83 amputacijana 1000 pacijent-godina). Prosječna dob pacijenata bila je 67,2 g, a 66% su činili muškarci, 
s prosječnim ITM 29,6±4,8 kg/m2 i trajanjem dijabetesa od 14,7±8,2 g. Nije ustanovljena povezanost između pušenja, 
arterijske hipertenzije, hiperlipidemije, terapije ACE inhibitorima i statinima, antiagregacijske terapije, KVB, te neu-
ropatije i trajanja dijabetesa do prve amputacije. Samo prethodno liječenje sulfonilurejom i inzulinom značajno je prod-
uljilo vrijeme do prve amputacije (p=0,00001, za obje terapije). U zaključku, godišnje stope amputacija donjih  ekstremiteta 
u oboljelih od šećerne bolesti su visoke u našoj županiji. Poznavanje stopa amputacija donjih ekstremiteta za regiju važna 
je zbog unaprijeđivanja skrbi dijabetičkih bolesnika te planiranja zdravstvene politike.
